1) American Society of Clinical Oncology. Multiple myeloma: overview. Disponible a
través de: http://www.cancer.net/cancer-types/multiple-myeloma/overview. Último acceso
18 de mayo de 2015.
2) Kumar, SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple
myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international
myeloma working group study. Leukemia. 2012;26(1):149-57.
3) Danylesko I, Beider K, Shimoni A, Nagler A. Monoclonal antibody-based immunotherapy
for multiple myeloma. Immunotherapy. 2012;4:919-38.
4) Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action
in multiple myeloma in 2013: a report from the International Myeloma Working Group
(IMWG). Leukemia. 2014;28:525-542.
5) Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306
cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-8.
6) Fedele G, di Girolamo M, Recine U, et al. CD38 ligation in peripheral blood
mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and
impaired secretion of IFNgamma cytokines and proliferation. Mediat Inflamm.
2013;2013:564687.
7) de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human
CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological
tumors. J Immunol. 2011;186:1840-8.
8) Lonial S, Weiss BM, Usmani SZ, et al. Phase 2 Study of daratumumab Monotherapy in
Patients with mayor o igual que3 Lines of Prior Therapy or Double Refractory Multiple
Myeloma (MM). J Clin Oncol. 2015;33(Suppl.):abstract LBA 8512.
9) Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy
in Multiple Myeloma. N Engl J Med. 2015;Aug:1-13.
10) European Medicines Agency. Public Summary of Orphan Drug Designations - EU/3/13/1153.
Disponible a través de:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2013/08/huma
n_orphan_001232.jsp&mid=WC0b01ac058001d12b Último acceso 12 de mayo de 2015.
11) GLOBOCAN 2012. Multiple myeloma. Disponible a través
de: http://globocan.iarc.fr/old/burden.asp?selection_pop=62968&Textp=Europe&selection
_cancer=17270&Text-c=Multiple+myeloma&pYear=13&type=0&window=1&submit=%C2%A0Execute.
Último acceso 13 de mayo de 2014.
12) American Cancer Society. Multiple myeloma: detailed guide. Disponible a través de:
http://www.cancer.org/acs/groups/cid/documents/webcontent/003121-pdf.pdf Último acceso
18 de mayo de 2015.
13) Cancer Research UK. Myeloma Survival Statistics. Disponible a través de:
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/survival/multipl
e-myeloma-survival-statistics Último acceso 18 de mayo de 2015.
14) Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia.
2015;29:1616-8.
Consultas de medios:
Natalie Buhl
Móvil: +353(0)85-744-6696
E-mail: nbuhl@its.jnj.com
EmptyBreak:MARKER
Relaciones con los inversores:
Lesley Fishman
Teléfono: +1-732-524-3922
EmptyBreak:MARKER
Louise Mehrotra
Teléfono: +1-732-524-6491
Septiembre de 2015
PHEM/DAT/0815/0002
.
.
Photo:
http://photos.prnewswire.com/prnh/20140324/NY88746LOGO
